DII Data: Stock Market today Insights for 22 Aug 2024

Below is a summary of the recent activities observed within the Domestic Investments for the clients: Alacrity Securities . Let’s delve into the details below to explore further.

Company Logo	Company	Client Name	Buy/Sell	Qty Traded	Price	Trader Name
	Navigant Corporate Advisors	Alacrity Securities	Sell	17K	36.10	Navigant Ir Services Private
	Pnb Housing Finance	Asia Opportunities V (mauritius)	Sell	7M	866.70	Government Of Singapore
		Government Of Singapore	Buy	1M	866.05	Asia Opportunities V (mauritius)
	Shriram Properties	Bnp Paribas Financial Markets	Buy	853K	126.85	Graviton Research Capital Llp
	Eris Lifesciences	Emerald Investments	Sell	9M	1201.00	Infinity Partners
	Niit	Hornbill Orchid India Fund	Sell	3M	118.00	Pawar Family Trust
	V2 Retail	India 2020 Fund Ii	Sell	700K	1056.17	F3 Advisors Private
	Kalyan Jewellers India	Motilal Oswal Mutual Fund	Buy	9M	539.10	Highdell Investment
		Nomura Funds Ireland Plc Nomura Funds Ireland India Equity Fund	Buy	7M	539.10	Highdell Investment
		Nomura India Investment Fund Mother Fund	Buy	11M	539.10	Highdell Investment
	Sanjivani Paranteral	Next Orbit Ventures Fund	Sell	100K	280.46	Na
	Milgrey Finance & Investment	Shreni Construction Private	Sell	5100	40.46	Multiplier Share & Stock Advisors Private

The 17K shares of Navigant Corporate Advisors have been sold by the by Alacrity Securities through Domestic Investments at a price of ₹36.10 per shareand it is purchased by Navigant Ir Services Private at a price of ₹36.10 per share.
The 7M shares of Pnb Housing Finance have been sold by the by Asia Opportunities V (mauritius) through Domestic Investments at a price of ₹866.70 per shareand it is purchased by Government Of Singapore at a price of ₹866.70 per share.
The 853K shares of Shriram Properties have been purchased by the by Bnp Paribas Financial Markets through Domestic Investments at a price of ₹126.85 per shareand it is sold by Graviton Research Capital Llp at a price of ₹126.85 per share.
The 9M shares of Eris Lifesciences have been sold by the by Emerald Investments through Domestic Investments at a price of ₹1201.00 per shareand it is purchased by Infinity Partners at a price of ₹1201.00 per share.
The 1M shares of Pnb Housing Finance have been purchased by the by Government Of Singapore through Domestic Investments at a price of ₹866.05 per shareand it is sold by Asia Opportunities V (mauritius) at a price of ₹866.05 per share.
The 3M shares of Niit have been sold by the by Hornbill Orchid India Fund through Domestic Investments at a price of ₹118.00 per shareand it is purchased by Pawar Family Trust at a price of ₹118.00 per share.
The 700K shares of V2 Retail have been sold by the by India 2020 Fund Ii through Domestic Investments at a price of ₹1056.17 per shareand it is purchased by F3 Advisors Private at a price of ₹1056.17 per share.
The 9M shares of Kalyan Jewellers India have been purchased by the by Motilal Oswal Mutual Fund through Domestic Investments at a price of ₹539.10 per shareand it is sold by Highdell Investment at a price of ₹539.10 per share.
The 100K shares of Sanjivani Paranteral have been sold by the by Next Orbit Ventures Fund through Domestic Investments at a price of ₹280.46 per share.
The 7M shares of Kalyan Jewellers India have been purchased by the by Nomura Funds Ireland Plc Nomura Funds Ireland India Equity Fund through Domestic Investments at a price of ₹539.10 per shareand it is sold by Highdell Investment at a price of ₹539.10 per share.
The 11M shares of Kalyan Jewellers India have been purchased by the by Nomura India Investment Fund Mother Fund through Domestic Investments at a price of ₹539.10 per shareand it is sold by Highdell Investment at a price of ₹539.10 per share.
The 5100 shares of Milgrey Finance & Investment have been sold by the by Shreni Construction Private through Domestic Investments at a price of ₹40.46 per shareand it is purchased by Multiplier Share & Stock Advisors Private at a price of ₹40.46 per share.

Company Logo	Company	Client Name	Buy/Sell	Qty Traded	Price	Trader Name
	Alkem Laboratories	Bnp Paribas Arbitrage -non Odi	Buy	35K	5732.15	Samprada&nanhamati Singh Family Trust
		Citigroup Global Markets Mauritius Private	Buy	35K	5732.15	Samprada&nanhamati Singh Family Trust
		Copthall Mauritius Investment -non Odi Account	Buy	17K	5732.15	Samprada&nanhamati Singh Family Trust
		Goldman Sachs Investments Mauritius I	Buy	35K	5732.15	Samprada&nanhamati Singh Family Trust
		Icici Prudential Life Insurance Company	Buy	197K	5732.15	Samprada&nanhamati Singh Family Trust
		Jm Financial Mutual Fund	Buy	17K	5732.15	Samprada&nanhamati Singh Family Trust
		Kotak Mahindra Mutual Fund	Buy	61K	5732.15	Samprada&nanhamati Singh Family Trust
		Morgan Stanley Asia Singapore Pte	Buy	35K	5732.15	Samprada&nanhamati Singh Family Trust
		Reliance Nippon Life Insurance Company	Buy	61K	5732.15	Samprada&nanhamati Singh Family Trust
		Societe Generale	Buy	46K	5732.15	Samprada&nanhamati Singh Family Trust
		Tata Mutual Fund	Buy	87K	5732.15	Samprada&nanhamati Singh Family Trust
	Eris Lifesciences	Emerald Investments	Sell	9M	1201.00	Infinity Partners
	Kalyan Jewellers India	Fidelity Funds – Sustainable Asia Equity Ii Pool	Buy	743K	539.10	Highdell Investment
		Fidelity Investment Funds – Fidelity Sustainable Asia Equity Fund	Buy	66K	539.10	Highdell Investment
		Government Of Singapore	Buy	7M	539.10	Highdell Investment
		Hsbc Mutual Fund	Buy	2M	539.10	Highdell Investment
		Invesco Mutual Fund A/c Invesco Tax Plan	Buy	1M	539.10	Highdell Investment
		Monetary Authority Of Singapore	Buy	1M	539.10	Highdell Investment
		Motilal Oswal Mutual Fund	Buy	9M	539.10	Highdell Investment
		Nomura Funds Ireland Plc-asia Ex Japan High Conviction Fund	Buy	1M	539.10	Highdell Investment
		Nomura India Investment Fund Mother Fund	Buy	11M	539.10	Highdell Investment
		Sundaram Mutual Fund	Buy	1M	539.10	Highdell Investment
		The Master Tr Bk Of Jpn As Trstee Of Fidelity Asia Eqty Mother Fd	Buy	62K	539.10	Highdell Investment
	Niit	Hornbill Orchid India Fund	Sell	3M	118.00	Pawar Family Trust

Alkem Laboratories shares totaling 35K were purchased by the by Bnp Paribas Arbitrage -non Odi of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.
Alkem Laboratories shares totaling 35K were purchased by the by Citigroup Global Markets Mauritius Private of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.
Alkem Laboratories shares totaling 17K were purchased by the by Copthall Mauritius Investment -non Odi Account of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.

Eris Lifesciences shares totaling 9M were sold by the by Emerald Investments of Domestic Investments, with the transaction occurring at a price of ₹1201.00 per share. Subsequently, the shares were purchased by Infinity Partners at the same price per share.
Kalyan Jewellers India shares totaling 743K were purchased by the by Fidelity Funds – Sustainable Asia Equity Ii Pool of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.
Kalyan Jewellers India shares totaling 66K were purchased by the by Fidelity Investment Funds – Fidelity Sustainable Asia Equity Fund of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.

Alkem Laboratories shares totaling 35K were purchased by the by Goldman Sachs Investments Mauritius I of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.
Kalyan Jewellers India shares totaling 7M were purchased by the by Government Of Singapore of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.
Niit shares totaling 3M were sold by the by Hornbill Orchid India Fund of Domestic Investments, with the transaction occurring at a price of ₹118.00 per share. Subsequently, the shares were purchased by Pawar Family Trust at the same price per share.

Kalyan Jewellers India shares totaling 2M were purchased by the by Hsbc Mutual Fund of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.
Alkem Laboratories shares totaling 197K were purchased by the by Icici Prudential Life Insurance Company of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.
Kalyan Jewellers India shares totaling 1M were purchased by the by Invesco Mutual Fund A/c Invesco Tax Plan of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.

Alkem Laboratories shares totaling 17K were purchased by the by Jm Financial Mutual Fund of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.
Alkem Laboratories shares totaling 61K were purchased by the by Kotak Mahindra Mutual Fund of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.
Kalyan Jewellers India shares totaling 1M were purchased by the by Monetary Authority Of Singapore of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.

Alkem Laboratories shares totaling 35K were purchased by the by Morgan Stanley Asia Singapore Pte of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.
Kalyan Jewellers India shares totaling 9M were purchased by the by Motilal Oswal Mutual Fund of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.
Kalyan Jewellers India shares totaling 1M were purchased by the by Nomura Funds Ireland Plc-asia Ex Japan High Conviction Fund of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.

Kalyan Jewellers India shares totaling 11M were purchased by the by Nomura India Investment Fund Mother Fund of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.
Alkem Laboratories shares totaling 61K were purchased by the by Reliance Nippon Life Insurance Company of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.
Alkem Laboratories shares totaling 46K were purchased by the by Societe Generale of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.

Kalyan Jewellers India shares totaling 1M were purchased by the by Sundaram Mutual Fund of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.
Alkem Laboratories shares totaling 87K were purchased by the by Tata Mutual Fund of Domestic Investments, with the transaction occurring at a price of ₹5732.15 per share. Subsequently, the shares were sold by Samprada&nanhamati Singh Family Trust at the same price per share.
Kalyan Jewellers India shares totaling 62K were purchased by the by The Master Tr Bk Of Jpn As Trstee Of Fidelity Asia Eqty Mother Fd of Domestic Investments, with the transaction occurring at a price of ₹539.10 per share. Subsequently, the shares were sold by Highdell Investment at the same price per share.

PNB Housing Finance Limited

In PNB Housing Finance Limited's recent financial report, the data highlights a robust performance. Net sales reached ₹18,125.30 million, with total income of ₹18,220.10 million. The expenditure was ₹12,632.80 million, leading to a net profit of ₹4,387.10 million. Earnings per Share (EPS) for continuing operations were reported at ₹16.89. The financial overview also includes other income of ₹94.80 million, finance costs of ₹10,972.50 million, and employee benefit expenses totaling ₹838.70 million. Depreciation and amortization expenses were ₹133.10 million. Current and deferred taxes were recorded at ₹1,440.70 million and ₹-240.50 million, respectively. The total comprehensive income for the period was ₹4,217.60 million, and other comprehensive income net of taxes was ₹-169.50 million.

Valued at ₹26,584 crore, the company's stock trades at ₹1,023, with historical highs and lows of ₹1,110 / 600. The P/E ratio of 16.7 reflects a high stock valuation. The book value is ₹577, and the dividend yield is 0.00%. ROCE is at 9.24%, and ROE is 11.6%. The company’s minimal debt-to-equity ratio of 3.67 contrasts with its negative net cash flow of ₹-1,669 crore. The Piotroski score is 4.00, and the Graham Number of ₹892 provides insight into the stock’s valuation. The Price-to-Book (P/B) ratio of 1.78 indicates a premium valuation.

Shriram Properties Limited

The latest financial figures for Shriram Properties Limited indicate a strong performance. The company achieved net sales of ₹1,539.60 million and total income of ₹2,109.00 million for the quarter. Expenditure was ₹1,867.40 million, resulting in a net profit of ₹174.60 million. Earnings per Share (EPS) for continuing operations stood at ₹1.02. The report also shows other income of ₹569.40 million, finance costs of ₹267.60 million, and employee benefit expenses of ₹229.60 million. Depreciation and amortization expenses totaled ₹26.50 million. Current tax expense was ₹0.70 million and deferred tax expense was ₹98.10 million. Total comprehensive income for the period was ₹174.70 million, with other comprehensive income net of taxes at ₹0.10 million.

Currently valued at ₹2,307 crore, the company's stock price is ₹135. It has seen a price range of ₹148 / 80.5 over time. The stock's Price-to-Earnings (P/E) ratio is notably high at 30.3, implying a strong valuation. The book value per share is ₹75.0 and the dividend yield is 0.00%. ROCE is recorded at 10.3%, and ROE stands at 6.09%. The company maintains a very low debt-to-equity ratio of 0.51, though it has a negative net cash flow of ₹35.0 crore. The Piotroski score of 8.00 and the Graham Number of ₹86.9 suggest some caution, while the Price-to-Book (P/B) ratio of 1.81 reflects a premium valuation.

Eris Lifesciences Limited

In Eris Lifesciences Limited's recent financial report, the data highlights a robust performance. Net sales reached ₹4,566.90 million, with total income of ₹4,618.50 million. The expenditure was ₹4,350.30 million, leading to a net profit of ₹170.40 million. Earnings per Share (EPS) for continuing operations were reported at ₹1.25. The financial overview also includes other income of ₹51.60 million, finance costs of ₹561.70 million, and employee benefit expenses totaling ₹1,037.50 million. Depreciation and amortization expenses were ₹455.50 million. Current and deferred taxes were recorded at ₹46.90 million and ₹50.90 million, respectively. The total comprehensive income for the period was ₹163.20 million, and other comprehensive income net of taxes was ₹-7.20 million.

Valued at ₹19,711 crore, the company's stock trades at ₹1,448, with historical highs and lows of ₹1,522 / 792. The P/E ratio of 52.2 reflects a high stock valuation. The book value is ₹190, and the dividend yield is 0.51%. ROCE is at 11.3%, and ROE is 16.3%. The company’s minimal debt-to-equity ratio of 1.08 contrasts with its negative net cash flow of ₹38.2 crore. The Piotroski score is 4.00, and the Graham Number of ₹346 provides insight into the stock’s valuation. The Price-to-Book (P/B) ratio of 7.62 indicates a premium valuation.

Niit Learning Systems Limited

The financial snapshot for Niit Learning Systems Limited reveals a noteworthy performance this quarter. Net sales amounted to ₹4,072.29 million and total income was ₹4,165.75 million. The company's expenditure was ₹3,324.23 million, leading to a net profit of ₹600.19 million. Earnings per Share (EPS) for continuing operations were ₹4.43. The report also highlights other income of ₹93.46 million, finance costs of ₹72.10 million, and employee benefit expenses of ₹1,950.11 million. Depreciation and amortization costs were ₹139.97 million, while current and deferred taxes were ₹178.72 million and ₹33.56 million, respectively. The total comprehensive income for the period stood at ₹586.88 million, with other comprehensive income net of taxes at ₹-13.31 million.

Currently valued at ₹7,132 crore, the company's stock price is ₹525. It has seen a price range of ₹577 / 342 over time. The stock's Price-to-Earnings (P/E) ratio is notably high at 32.0, implying a strong valuation. The book value per share is ₹72.2 and the dividend yield is 0.99%. ROCE is recorded at 33.6%, and ROE stands at 24.8%. The company maintains a very low debt-to-equity ratio of 0.14, though it has a negative net cash flow of ₹28.4 crore. The Piotroski score of 6.00 and the Graham Number of ₹162 suggest some caution, while the Price-to-Book (P/B) ratio of 7.26 reflects a premium valuation.

V2 Retail Limited

The latest financial figures for V2 Retail Limited indicate a strong performance. The company achieved net sales of ₹4,150.33 million and total income of ₹4,164.26 million for the quarter. Expenditure was ₹3,946.56 million, resulting in a net profit of ₹163.40 million. Earnings per Share (EPS) for continuing operations stood at ₹4.72. The report also shows other income of ₹13.93 million, finance costs of ₹137.13 million, and employee benefit expenses of ₹356.19 million. Depreciation and amortization expenses totaled ₹213.68 million. Current tax expense was ₹50.34 million and deferred tax expense was ₹3.96 million. Total comprehensive income for the period was ₹161.90 million, with other comprehensive income net of taxes at ₹-1.50 million.

The company's market cap is ₹3,772 crore, with a stock price of ₹1,091. The historical stock range has been between ₹1,247 / 133. Its Price-to-Earnings (P/E) ratio of 99.8 indicates a high valuation. The book value per share is ₹79.4, and it has a dividend yield of 0.00%. The ROCE is 10.7% and ROE is 10.7%. With a very low debt-to-equity ratio of 1.91, the company is minimally leveraged. However, it reports a negative net cash flow of ₹4.53 crore. The Piotroski score of 7.00 and the Graham Number of ₹140 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 13.7 suggests the stock is trading at a premium.

Kalyan Jewellers India Limited

In Kalyan Jewellers India Limited's recent financial report, the data highlights a robust performance. Net sales reached ₹55,354.79 million, with total income of ₹55,576.37 million. The expenditure was ₹53,201.46 million, leading to a net profit of ₹1,775.58 million. Earnings per Share (EPS) for continuing operations were reported at ₹1.73. The financial overview also includes other income of ₹221.58 million, finance costs of ₹852.25 million, and employee benefit expenses totaling ₹1,724.32 million. Depreciation and amortization expenses were ₹754.69 million. Current and deferred taxes were recorded at ₹894.99 million and ₹-295.66 million, respectively. The total comprehensive income for the period was ₹1,757.02 million, and other comprehensive income net of taxes was ₹-18.56 million.

With a market capitalization of ₹66,324 crore, the company’s stock is currently priced at ₹643. The historical trading range of the stock is ₹663 / 203. The P/E ratio is remarkably high at 105, suggesting a significant valuation. The book value stands at ₹40.7, and the dividend yield is 0.19%. The Return on Capital Employed (ROCE) is 14.0%, and the Return on Equity (ROE) is 15.2%. The debt-to-equity ratio is very low at 1.07, though the company shows a negative net cash flow of ₹36.8 crore. The Piotroski score is 7.00, with the Graham Number pegged at ₹74.9. The Price-to-Book (P/B) ratio of 15.8 highlights a premium valuation.

Sanjivani Paranteral Ltd.

In Sanjivani Paranteral Ltd.'s recent financial report, the data highlights a robust performance. Net sales reached ₹0.00 million, with total income of ₹165.23 million. The expenditure was ₹-142.49 million, leading to a net profit of ₹17.14 million. Earnings per Share (EPS) for continuing operations were reported at ₹1.47. The financial overview also includes other income of ₹0.86 million, finance costs of ₹-0.16 million, and employee benefit expenses totaling ₹-11.27 million. Depreciation and amortization expenses were ₹-1.33 million. Current and deferred taxes were recorded at ₹-5.60 million and ₹0.00 million, respectively. The total comprehensive income for the period was ₹0.00 million, and other comprehensive income net of taxes was ₹0.00 million.

The company's market cap is ₹250 crore, with a stock price of ₹214. The historical stock range has been between ₹233 / 62.0. Its Price-to-Earnings (P/E) ratio of 40.5 indicates a high valuation. The book value per share is ₹23.9, and it has a dividend yield of 0.00%. The ROCE is 55.3% and ROE is 49.7%. With a very low debt-to-equity ratio of 0.03, the company is minimally leveraged. However, it reports a negative net cash flow of ₹0.24 crore. The Piotroski score of 4.00 and the Graham Number of ₹53.2 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 8.98 suggests the stock is trading at a premium.

Alkem Laboratories Limited

The latest financial figures for Alkem Laboratories Limited indicate a strong performance. The company achieved net sales of ₹25,001.00 million and total income of ₹26,062.00 million for the quarter. Expenditure was ₹19,652.60 million, resulting in a net profit of ₹5,832.50 million. Earnings per Share (EPS) for continuing operations stood at ₹48.78. The report also shows other income of ₹1,061.00 million, finance costs of ₹214.40 million, and employee benefit expenses of ₹4,259.00 million. Depreciation and amortization expenses totaled ₹643.50 million. Current tax expense was ₹1,112.60 million and deferred tax expense was ₹-535.70 million. Total comprehensive income for the period was ₹5,807.70 million, with other comprehensive income net of taxes at ₹-24.80 million.

The company's market cap is ₹75,445 crore, with a stock price of ₹6,310. The historical stock range has been between ₹6,347 / 3,440. Its Price-to-Earnings (P/E) ratio of 35.2 indicates a high valuation. The book value per share is ₹862, and it has a dividend yield of 0.63%. The ROCE is 19.7% and ROE is 19.6%. With a very low debt-to-equity ratio of 0.14, the company is minimally leveraged. However, it reports a negative net cash flow of ₹-207 crore. The Piotroski score of 9.00 and the Graham Number of ₹1,826 show mixed financial indicators, while the Price-to-Book (P/B) ratio of 7.32 suggests the stock is trading at a premium.

Join our telegram for more updates

Stay Updated with Our YouTube Videos